BeyondSpring (BeyondSpring) Growth Rank : 0 (As of Jun. 06, 2024)

View and export this data going back to 2017. Start your Free Trial

What is BeyondSpring Growth Rank?

BeyondSpring has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

BeyondSpring Growth Rank Related Terms

Thank you for viewing the detailed overview of BeyondSpring's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BeyondSpring (BeyondSpring) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeyondSpring Inc (NAS:BYSI) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Liberty Street, 39th Floor, New York, NY, USA, 10005

Website

https://www.beyondspringpharma.com

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform. It has a scalable business model integrating clinical resources in the United States and China.